Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells 4,041 Shares of Stock

Key Points

• Lai Wang, an insider at BeOne Medicines Ltd., sold 4,041 shares at an average price of $302.49, decreasing their ownership by 93.98%.
• BeOne Medicines' stock experienced a trading volume of 503,014 shares on Thursday, with the stock price reaching $301.13, against a 52-week low of $155.75.
• Several research firms have recently upgraded BeOne Medicines' stock, leading to a consensus buy rating and a target price of $327.56.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 4,041 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $302.49, for a total transaction of $1,222,362.09. Following the completion of the sale, the insider owned 259 shares of the company's stock, valued at $78,344.91. This trade represents a 93.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lai Wang also recently made the following trade(s):

• On Wednesday, July 30th, Lai Wang sold 259 shares of BeOne Medicines stock. The shares were sold at an average price of $305.00, for a total transaction of $78,995.00.
• On Friday, July 18th, Lai Wang sold 700 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total transaction of $210,000.00.
• On Monday, June 23rd, Lai Wang sold 1,028 shares of BeOne Medicines stock. The shares were sold at an average price of $260.00, for a total transaction of $267,280.00.
• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The shares were sold at an average price of $251.37, for a total transaction of $118,143.90.
• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total transaction of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The shares were sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Stock Down 0.7%

BeOne Medicines stock traded down $2.12 on Friday, hitting $299.01. The company's stock had a trading volume of 543,060 shares, compared to its average volume of 402,877. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of -80.38 and a beta of 0.27. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $263.99. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $155.75 and a one year high of $308.87.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. Analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ONC. JPMorgan Chase & Co. lifted their price target on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. TD Securities reaffirmed a "buy" rating and set a $334.00 target price on shares of BeOne Medicines in a research report on Thursday, April 24th. Wall Street Zen raised shares of BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Morgan Stanley boosted their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research report on Friday, June 27th. Finally, Guggenheim boosted their target price on shares of BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $327.56.

Institutional Investors Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the business. Envestnet Asset Management Inc. acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $15,061,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $7,150,000. Asset Management One Co. Ltd. acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $4,951,000. Slow Capital Inc. acquired a new position in BeOne Medicines during the 2nd quarter worth about $4,377,000. Finally, Public Employees Retirement System of Ohio acquired a new position in BeOne Medicines during the 2nd quarter worth about $3,491,000. Institutional investors own 48.55% of the company's stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.